Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Raanan Berger et al.|Journal of Clinical Oncology|2016Cited by 859
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I. Haddad, Ranee Mehra, Tanguy Y. Seiwert et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 96
Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).Laura Q.M. Chow, Tanguy Y. Seiwert, Ranee Mehra et al.|Journal of Clinical Oncology|2016Cited by 31